The CD33 surface protein is an attractive immunotherapy target for acute leukemia, but is also expressed on normal haematopoietic cells and therefore epitope editing of CD33 in HSCs would allow for the application of CD33-targeting immunotherapies concomitant with the continuation of normal haematopoiesis43–46. Here, CD33 is linked to acute leukemia.